Rujuta Gadkari

Mumbai, MH, India

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Real-World Evaluation of the Episoft® AC Moisturizer With Broad-Spectrum Sunscreen in the Management of Retinoid-Induced Dermatitis: A Retrospective Observational Study.

Real-World Evaluation of the Episoft® AC Moisturizer With Broad-Spectrum Sunscreen in the Management of Retinoid-Induced Dermatitis: A Retrospective Observational Study.

Journal: Cureus

Published: May 09, 2026

PROMISE‑MINO: A Prospective, Open‑Label, Multicenter, Single‑Arm, Phase IV Study of the Safety, Local Tolerability, and Efficacy of Topical Minocycline Hydrochloride 4% Gel in Indian Patients With Moderate‑to‑Severe Acne Vulgaris.

PROMISE‑MINO: A Prospective, Open‑Label, Multicenter, Single‑Arm, Phase IV Study of the Safety, Local Tolerability, and Efficacy of Topical Minocycline Hydrochloride 4% Gel in Indian Patients With Moderate‑to‑Severe Acne Vulgaris.

Journal: Cureus

Published: January 15, 2026

An Open-Label, Single-Arm, Multicentric, Prospective, Phase IV Study to Evaluate the Safety and Effectiveness of Indacaterol/Mometasone/Glycopyrronium Dry Powder Inhaler (DPI) in the Management of Asthma Patients (OASIS Study).

An Open-Label, Single-Arm, Multicentric, Prospective, Phase IV Study to Evaluate the Safety and Effectiveness of Indacaterol/Mometasone/Glycopyrronium Dry Powder Inhaler (DPI) in the Management of Asthma Patients (OASIS Study).

Journal: Cureus

Published: December 29, 2025

Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study.

Triple arm, prospective, real-world study comparing the efficacy of FDC teneligliptin + dapagliflozin to FDC sitagliptin + dapagliflozin, and FDC linagliptin + empagliflozin in Indian type 2 diabetes mellitus patients using CGM device: the Amplify-TIR study.

Journal: Cardiovascular diabetology. Endocrinology reports

Published: June 13, 2025

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).

A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV).

Journal: Clinical diabetes and endocrinology

Published: September 16, 2024

Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study).

Are Two Gliflozins Different: A Prospective Multicenter Randomized Study to Assess Effect of Remogliflozin Compared With Empagliflozin on Biomarkers of Heart Failure in Indian Patients With Type 2 Diabetes Mellitus with Chronic Heart Failure (REMIT-HF Study).

Journal: Journal of cardiac failure

Published: June 19, 2024

The Indian REgistry on Current Patient PrOfiles and TReatment TrenDs in Hypertension (RECORD): Final Outcomes of the Real-world Observational Study.

The Indian REgistry on Current Patient PrOfiles and TReatment TrenDs in Hypertension (RECORD): Final Outcomes of the Real-world Observational Study.

Journal: The Journal of the Association of Physicians of India

Published: May 09, 2024

Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.

Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial.

Journal: Drug design, development and therapy

Published: May 30, 2023

Showing 1-8 of 8

Last Updated: 09/26/2026